Chronic Kidney Disease Trial, Recruiting NCT06126016 Sponsor: Boryung Pharmaceutical Co., Ltd Condition: Chronic Kidney Disease
Back to Chronic Kidney Disease

Chronic Kidney Disease Trial, Recruiting

NCT06126016
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are on hemodialysis and have been diagnosed with overactive parathyroid glands caused by chronic kidney disease (a condition called secondary hyperparathyroidism), where their treating doctor has planned to give them a medication called Pacitol Injection based on its prescribing guidelines.
  • People who have voluntarily signed a written consent form agreeing to have their personal information collected and used, after being given a full explanation of the study's purpose and methods.
  • People who are able to understand the study, cooperate with its requirements, and commit to participating until it is completed.

Who may not be able to join:

  • People who have previously had an allergic or hypersensitivity reaction to this medication or any of its ingredients.
  • People who show signs of having too much vitamin D in their body (vitamin D toxicity).
  • People who have high calcium levels in their blood at the time of enrolling in the trial.
  • Women who are pregnant or currently breastfeeding.
  • People who have a growth on a parathyroid gland (called a parathyroid adenoma) and are scheduled to have surgery to remove it.
  • People who have taken part in another clinical trial and received an experimental drug within the 12 weeks before the study's first visit.
  • People considered ineligible by the lead doctor or another supervising doctor on the study team.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +82-2-708-8000

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Boryung Pharmaceutical Co., Ltd
Registry
ClinicalTrials.gov
Start date
19 October 2023
Est. completion
1 April 2026

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

Proportion of subjects whose intact parathyroid hormone level applies to the therapeutic area(CKD 5D)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov